Patents Assigned to Regenesance B.V.
  • Antibodies that bind human C6 and uses thereof
    Patent number: 12194091
    Abstract: Isolated monoclonal antibodies that bind to human complement component C6 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic methods for using the antibodies.
    Type: Grant
    Filed: February 14, 2023
    Date of Patent: January 14, 2025
    Assignee: REGENESANCE B.V.
    Inventors: Frank Baas, Marc A. Van Dijk
  • Antibodies that bind human C6 and uses thereof
    Patent number: 11590222
    Abstract: Isolated monoclonal antibodies that bind to human complement component C6 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic methods for using the antibodies.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: February 28, 2023
    Assignee: Regenesance B.V.
    Inventors: Frank Baas, Marc A. Van Dijk
  • Antibodies that bind human C6 and uses thereof
    Patent number: 10675348
    Abstract: Isolated monoclonal antibodies that bind to human complement component C6 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic methods for using the antibodies.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: June 9, 2020
    Assignee: Regenesance B.V.
    Inventors: Frank Baas, Marc A. Van Dijk
  • COMPLEMENT ANTAGONISTS AND USES THEREOF
    Publication number: 20150211003
    Abstract: Disclosed are antagonists designed to inhibit or block expression of a mammalian complement such as complement component 6 (C6). The invention has a wide range of uses including use in the preparation of a medicament for the enhancement of nerve regeneration following acute or chronic nerve damage in a mammal. Additional applications include use in the treatment of multiple sclerosis either alone or in combination with another drug.
    Type: Application
    Filed: March 12, 2014
    Publication date: July 30, 2015
    Applicant: REGENESANCE B.V.
    Inventors: Frank BAAS, Kees FLUITER
  • Complement antagonists and uses thereof
    Patent number: 9089555
    Abstract: Disclosed are antagonists designed to inhibit or block expression of a mammalian complement such as complement component 6 (C6). The invention has a wide range of uses including use in the preparation of a medicament for the enhancement of nerve regeneration following acute or chronic nerve damage in a mammal. Additional applications include use in the treatment of multiple sclerosis either alone or in combination with another drug.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: July 28, 2015
    Assignee: Regenesance B.V.
    Inventors: Frank Baas, Kees Fluiter
  • COMPLEMENT ANTAGONISTS AND USES THEREOF
    Publication number: 20140301982
    Abstract: Disclosed are antagonists designed to inhibit or block expression of a mammalian complement such as complement component 6 (C6). The invention has a wide range of uses including use in the preparation of a medicament for the enhancement of nerve regeneration following acute or chronic nerve damage in a mammal. Additional applications include use in the treatment of multiple sclerosis either alone or in combination with another drug.
    Type: Application
    Filed: March 12, 2014
    Publication date: October 9, 2014
    Applicant: REGENESANCE B.V.
    Inventors: Frank BAAS, Kees FLUITER
  • COMPLEMENT INHIBITION FOR IMPROVED NERVE REGENERATION
    Publication number: 20140255395
    Abstract: The present invention relates to methods and medicaments used for treating conditions that require axonal regeneration, e.g. in mammals affected by injury or disease of the central or peripheral nervous system. The medicaments used in these methods facilitate axonal regeneration by inhibition of the complement system. Conditions requiring axonal regeneration that may be treated in accordance with the invention include physical injuries as well as neurodegenerative disorders of the peripheral or central nervous system.
    Type: Application
    Filed: March 12, 2014
    Publication date: September 11, 2014
    Applicant: REGENESANCE B.V.
    Inventors: Frank BAAS, Valeria RAMAGLIA
  • Complement antagonists and uses thereof
    Patent number: 8703730
    Abstract: Disclosed are antagonists designed to inhibit or block expression of a mammalian complement such as complement component 6 (C6). The invention has a wide range of uses including use in the preparation of a medicament for the enhancement of nerve regeneration following acute or chronic nerve damage in a mammal. Additional applications include use in the treatment of multiple sclerosis either alone or in combination with another drug.
    Type: Grant
    Filed: July 10, 2009
    Date of Patent: April 22, 2014
    Assignee: Regenesance B.V.
    Inventors: Frank Baas, Kees Fluiter
  • Complement inhibition for improved nerve regeneration
    Patent number: 8703136
    Abstract: The present invention relates to methods and medicaments used for treating conditions that require axonal regeneration, e.g. in mammals affected by injury or disease of the central or peripheral nervous system. The medicaments used in these methods facilitate axonal regeneration by inhibition of the complement system. Conditions requiring axonal regeneration that may be treated in accordance with the invention include physical injuries as well as neurodegenerative disorders of the peripheral or central nervous system.
    Type: Grant
    Filed: October 10, 2007
    Date of Patent: April 22, 2014
    Assignee: Regenesance B.V.
    Inventors: Frank Baas, Valeria Ramaglia